
As outlined in GTX’s Form 8K filing (US Securities and Exchange Commission form), MNX has committed to buying and activating a minimum of 15,000 devices over the next three years and anticipates beginning deployment of 2,000 to 3,000 units sometime in the 3rd and 4th quarter of 2010. MNX will initially use them to track medical and bio-pharmaceutical shipments and eventually roll them out for all their high-value, sensitive shipments.

“Real-time GPS tracking technology is game-changing for us and now we will be able to address any inquiry about the location and path of the thousands of critical shipments we manage for our customers.” says Scott Cannon, CEO of MNX. “By enabling both our clients and airline partners to have full transparency regarding their shipments, MNX will offer a unique layer of service, security, temperature integrity and reliability. GTX is at the forefront of this technology and it offers a significant improvement over anything else available in the industry, and we are excited about the opportunity to work with them to pioneer its commercial use.” In collaboration with prominent industry experts, this customized solution will greatly enhance the value proposition MNX already provides to the life sciences, medical and pharmaceutical transportation business. MNX is headquartered in Los Angeles with twenty-seven offices in eight countries.

